Claims for Patent: 8,609,831

Summary for Patent: 8,609,831

Title:	RNA-mediated gene modulation
Abstract:	An isolated RNA comprising an intron RNA that is released in a cell, thereby modulating the function of a target gene. Also disclosed are a composition comprising a chemokine and an isolated RNA of the invention or a DNA template for the isolated RNA, a composition comprising one or more agents that induce RNA-mediated modulation of the functions of two or more target genes in a cell, and methods of using these compositions for modulating the functions of genes in a cell.
Inventor(s):	Lin; Shi-Lung (Alhambra, CA), Ying; Shao-Yao (San Marino, CA)
Assignee:	University of Southern California (Los Angeles, CA)
Application Number:	10/663,875
Patent Claims:	1. An isolated RNA comprising: an artificial intron comprising a splice donor site, a splice acceptor site, a branch site, a poly-pyrimidine tract and at least one aberrant RNA selected from the group consisting of a short-temporary RNA, small-interfering RNA, short-hairpin RNA, long deoxyribonucleotide-containing RNA and ribozyme RNA, wherein said aberrant RNA is an RNA capable of silencing a target gene when released in a cell. 2. The isolated RNA of claim 1, wherein the cell is a mammalian cell. 3. The isolated RNA of claim 1, wherein the splice donor site contains 5'-AGGUAAGU-3'. 4. The isolated RNA of claim 1, wherein the splice acceptor site contains 5'-CCACAGC-3'. 5. The isolated RNA of claim 1, wherein the branch site contains 5'-UACUAAC-3. 6. The isolated RNA of claim 1, wherein the cell is a eukaryotic cell. 7. An isolated RNA comprising: an artificial intron RNA comprising at least one aberrant RNA selected from the group consisting of a short-temporary RNA, small-interfering RNA, short-hairpin RNA, long deoxyribonucleotide-containing RNA (D-RNA) and ribozyme RNA, said aberrant RNA being capable of silencing a target gene when released in a eukaryotic cell and wherein the artificial intron RNA further comprises a splice donor site that includes 5'-AGGUAAGU-3', a splice acceptor site that includes 5'-CCACAGC-3', a branch site that includes 5'-UACUAAC-3', a poly-pyrimidine tract that includes 5'-UUCUUUUUUUC-3' (SEQ ID NO:2), or a combination thereof. 8. A cultivated cell comprising the isolated RNA of claim 1. 9. A composition comprising the isolated RNA of claim 1. 10. The isolated RNA of claim 1, wherein the artificial intron contains a sequence that targets an exon of the target gene, wherein the target gene is integrin .beta.1. 11. The isolated RNA of claim 6, wherein the artificial intron contains a sequence that targets an exon of the target gene, wherein the target gene is integrin .beta.1. 12. The isolated RNA of claim 7, wherein the artificial intron contains a sequence that targets an exon of the target gene, wherein the target gene is integrin .beta.1.

Details for Patent 8,609,831

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2022-09-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2022-09-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2022-09-16